| MeSH term | MeSH ID | Detail |
|---|---|---|
| Weight Loss | D015431 | 56 associated lipids |
| Dermatitis, Contact | D003877 | 59 associated lipids |
| Pain | D010146 | 64 associated lipids |
| Cystic Fibrosis | D003550 | 65 associated lipids |
| Reperfusion Injury | D015427 | 65 associated lipids |
| Liver Cirrhosis | D008103 | 67 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Colitis | D003092 | 69 associated lipids |
| Hyperlipidemias | D006949 | 73 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Atherosclerosis | D050197 | 85 associated lipids |
| Diabetes Mellitus, Experimental | D003921 | 85 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Seizures | D012640 | 87 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Brain Ischemia | D002545 | 89 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Jain A et al. | Pregnancy after liver transplantation under tacrolimus. | 1997 | Transplantation | pmid:9293865 |
| Garcia-Criado FJ et al. | Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. | 1997 | Transplantation | pmid:9293871 |
| Suzuki H et al. | Induction of transplantation tolerance in adult rats by vascularized spleen transplantation. | 1997 | Transplantation | pmid:9293881 |
| Satterthwaite R et al. | Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. | 1998 | Transplantation | pmid:9484771 |
| Garrity ER and Mehra MR | An update on clinical outcomes in heart and lung transplantation. | 2004 | Transplantation | pmid:15201689 |
| First MR and Fitzsimmons WE | New drugs to improve transplant outcomes. | 2004 | Transplantation | pmid:15201693 |
| Takaya S et al. | The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. | 1992 | Transplantation | pmid:1371195 |
| Francavilla A et al. | Inhibition of liver, kidney, and intestine regeneration by rapamycin. | 1992 | Transplantation | pmid:1371198 |
| Bayer ND et al. | Association of metabolic syndrome with development of new-onset diabetes after transplantation. | 2010 | Transplantation | pmid:20724958 |
| Sheikh AM et al. | Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. | 1999 | Transplantation | pmid:10440408 |
| Moxey-Mims MM | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1999 | Transplantation | pmid:10440413 |
| Pratschke J et al. | Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. | 1997 | Transplantation | pmid:9326428 |
| McGhee B et al. | Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients. | 1997 | Transplantation | pmid:9326429 |
| Jain AB et al. | Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. | 2004 | Transplantation | pmid:15077034 |
| High KP | The antimicrobial activities of cyclosporine, FK506, and rapamycin. | 1994 | Transplantation | pmid:7517076 |
| Weir MR et al. | Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. | 2017 | Transplantation | pmid:26950714 |
| Yoshimura N et al. | The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. | 1994 | Transplantation | pmid:7517078 |
| Ravindran VK et al. | Insulin hyposecretion in nondiabetic, tacrolimus-treated renal transplant recipients more than 6 months posttransplantation. | 2009 | Transplantation | pmid:19543067 |
| Tuteja S et al. | The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. | 2001 | Transplantation | pmid:11397967 |
| Maes BD et al. | Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. | 2001 | Transplantation | pmid:11726827 |
| Kahan BD | An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy. | 1999 | Transplantation | pmid:10428260 |
| Washburn K et al. | Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. | 2001 | Transplantation | pmid:11726831 |
| Reichenspurner H et al. | Optimization of the immunosuppressive protocol after lung transplantation. | 1999 | Transplantation | pmid:10428269 |
| Pilmore HL et al. | Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. | 2001 | Transplantation | pmid:11726837 |
| Moxey-Mims MM et al. | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1998 | Transplantation | pmid:9521193 |
| Hytiroglou P et al. | FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. | 1993 | Transplantation | pmid:7506452 |
| Ishizuka J et al. | Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. | 1993 | Transplantation | pmid:7506454 |
| Heilman RL et al. | Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal. | 2012 | Transplantation | pmid:22067270 |
| Mourad G et al. | Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial. | 2017 | Transplantation | pmid:27547871 |
| Shapiro R et al. | Pediatric renal transplantation under tacrolimus-based immunosuppression. | 1999 | Transplantation | pmid:10075598 |
| Kaplan B et al. | Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. | 1999 | Transplantation | pmid:10075604 |
| Min DI et al. | Circadian variation of tacrolimus disposition in liver allograft recipients. | 1996 | Transplantation | pmid:8900327 |
| Jindal RM et al. | Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. | 1994 | Transplantation | pmid:7519799 |
| David-Neto E et al. | Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. | 2017 | Transplantation | pmid:27482958 |
| Mor E et al. | Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. | 1994 | Transplantation | pmid:7519800 |
| Heilman RL et al. | Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. | 2011 | Transplantation | pmid:21775930 |
| Ciancio G et al. | A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. | 2006 | Transplantation | pmid:16570006 |
| Erden E et al. | Plasma FK506 levels in patients with histopathologically documented renal allograft rejection. | 1994 | Transplantation | pmid:7519801 |
| Reddy KS et al. | Simultaneous kidney-pancreas transplantation without antilymphocyte induction. | 2000 | Transplantation | pmid:10653379 |
| Morikawa K et al. | The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. | 1992 | Transplantation | pmid:1281561 |
| Jain A et al. | Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. | 2000 | Transplantation | pmid:10653398 |
| Jevnikar A et al. | Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. | 2008 | Transplantation | pmid:18852662 |
| Yamazaki S et al. | Transplantation-related thrombotic microangiopathy triggered by preemptive therapy for hepatitis C virus infection. | 2008 | Transplantation | pmid:18852671 |
| Stevens RB et al. | A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. | 2015 | Transplantation | pmid:25083614 |
| Ravaioli M et al. | Immunosuppression Modifications Based on an Immune Response Assay: Results of a Randomized, Controlled Trial. | 2015 | Transplantation | pmid:25757214 |
| Ninova D et al. | Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. | 2004 | Transplantation | pmid:15316360 |
| Ciancio G et al. | The use of Campath-1H as induction therapy in renal transplantation: preliminary results. | 2004 | Transplantation | pmid:15316372 |
| Naesens M and Sarwal MM | Monitoring calcineurin inhibitor therapy: localizing the moving target. | 2010 | Transplantation | pmid:20458272 |
| Herlenius G et al. | Chronic kidney disease--a common and serious complication after intestinal transplantation. | 2008 | Transplantation | pmid:18622286 |
| Ceulemans LJ et al. | Nonsteroidal anti-inflammatory drug-induced intestinal graft loss 12 years after transplantation. | 2015 | Transplantation | pmid:25695790 |
| Watson MJ et al. | Renal function impacts outcomes after intestinal transplantation. | 2008 | Transplantation | pmid:18622288 |
| Berg UB et al. | Renal function before and long after liver transplantation in children. | 2001 | Transplantation | pmid:11544422 |
| Murase N et al. | Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. | 1993 | Transplantation | pmid:7682735 |
| Gruessner RW et al. | Mycophenolate mofetil in pancreas transplantation. | 1998 | Transplantation | pmid:9721799 |
| Emond JC et al. | Improved results of living-related liver transplantation with routine application in a pediatric program. | 1993 | Transplantation | pmid:7682738 |
| Laskow DA et al. | An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. | 1996 | Transplantation | pmid:8878381 |
| Woodle ES et al. | Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. | 1996 | Transplantation | pmid:8878382 |
| Kershner RP and Fitzsimmons WE | Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. | 1996 | Transplantation | pmid:8878385 |
| McLaren A | Tacrolimus pharmacogenetics: bringing the laboratory into the clinic. | 2003 | Transplantation | pmid:14705621 |
| Tanaka A et al. | Living related liver transplantation across ABO blood groups. | 1994 | Transplantation | pmid:7522363 |
| Devlin J et al. | Nitric oxide generation. A predictive parameter of acute allograft rejection. | 1994 | Transplantation | pmid:7522365 |
| Florescu DF et al. | Adenovirus infections in pediatric small bowel transplant recipients. | 2010 | Transplantation | pmid:20467354 |
| Jun KR et al. | Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. | 2009 | Transplantation | pmid:19384171 |
| Roberts CA et al. | Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. | 2002 | Transplantation | pmid:12364862 |
| Vafadari R et al. | Inhibitory effect of tacrolimus on p38 mitogen-activated protein kinase signaling in kidney transplant recipients measured by whole-blood phosphospecific flow cytometry. | 2012 | Transplantation | pmid:22643331 |
| Morales JM et al. | Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. | 2008 | Transplantation | pmid:18724234 |
| Opelz G and Döhler B | Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. | 2008 | Transplantation | pmid:18698238 |
| Vincenti F et al. | A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. | 2002 | Transplantation | pmid:11907427 |
| Gallon LG et al. | Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. | 2007 | Transplantation | pmid:17519781 |
| Jordan ML et al. | Tacrolimus rescue therapy for renal allograft rejection--five-year experience. | 1997 | Transplantation | pmid:9020321 |
| Langrehr JM et al. | Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. | 1992 | Transplantation | pmid:1384185 |
| McCarthy SA et al. | The effects of immunosuppressive drugs on the regulation of activation-induced apoptotic cell death in thymocytes. | 1992 | Transplantation | pmid:1384186 |
| Dhar DK et al. | The salutary effect of FK506 in ischemia-reperfusion injury of the canine liver. | 1992 | Transplantation | pmid:1384188 |
| Bashuda H et al. | Induction of persistent allograft tolerance in the rat by combined treatment with anti-leukocyte function-associated antigen-1 and anti-intercellular adhesion molecule-1 monoclonal antibodies, donor-specific transfusion, and FK506. | 1996 | Transplantation | pmid:8693525 |
| Egashira K et al. | Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. | 2003 | Transplantation | pmid:12698101 |
| Ericzon BG et al. | FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. | 1992 | Transplantation | pmid:1384189 |
| Hu H et al. | Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. | 2003 | Transplantation | pmid:12698107 |
| Wennberg L et al. | The efficacy of CD40 ligand blockade in discordant pig-to-rat islet xenotransplantation is correlated with an immunosuppressive effect of immunoglobulin. | 2005 | Transplantation | pmid:15665763 |
| Hebert MF et al. | Interpreting tacrolimus concentrations during pregnancy and postpartum. | 2013 | Transplantation | pmid:23274970 |
| Fujishiro J et al. | Immunologic benefits of longer graft in rat allogenic small bowel transplantation. | 2005 | Transplantation | pmid:15665767 |
| Arai K et al. | Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. | 1989 | Transplantation | pmid:2479130 |
| Raggi MC et al. | Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients' outcomes after renal transplantation. | 2010 | Transplantation | pmid:21076373 |
| Thai NL et al. | Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. | 2006 | Transplantation | pmid:17198253 |
| Ueki S et al. | Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. | 2006 | Transplantation | pmid:17198266 |
| Fredericks S and Holt DW | TGF-beta quantitation can be tricky. | 1999 | Transplantation | pmid:10480399 |
| Hughes JR et al. | Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. | 1999 | Transplantation | pmid:10480422 |
| Cacciarelli TV et al. | Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. | 1998 | Transplantation | pmid:9808490 |
| Holman MJ et al. | FK506-associated thrombotic thrombocytopenic purpura. | 1993 | Transplantation | pmid:7678357 |
| Todo S et al. | Small intestinal transplantation in humans with or without the colon. | 1994 | Transplantation | pmid:7512291 |
| Griffith BP et al. | A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. | 1994 | Transplantation | pmid:7512292 |
| Sun S et al. | Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. | 1996 | Transplantation | pmid:8633368 |
| Gruber SA and Doshi MD | Conversion to sirolimus in African American renal allograft recipients undergoing early steroid withdrawal: intermediate-term risks and benefits. | 2010 | Transplantation | pmid:20440195 |
| Aisa Y et al. | Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. | 2005 | Transplantation | pmid:16278584 |
| Tanaka J et al. | The immunosuppressive agent FK506 enhances the cytolytic activity of inhibitory natural killer cell receptor (CD94/NKG2A)-expressing CD8 T cells. | 2005 | Transplantation | pmid:16378079 |
| Markus PM et al. | Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. | 1991 | Transplantation | pmid:1718063 |
| Ryu S and Yasunami Y | The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. | 1991 | Transplantation | pmid:1718064 |
| Wang HD et al. | Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation. | 2018 | Transplantation | pmid:29298238 |
| Starzl TE et al. | Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. | 1991 | Transplantation | pmid:1718068 |
| Dharancy S et al. | Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. | 2007 | Transplantation | pmid:17460561 |
| Vadivel N et al. | Tacrolimus dose in black renal transplant recipients. | 2007 | Transplantation | pmid:17460575 |